{"classes":[{"categories":[{"measurements":[{"comment":"The Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing which resulted in insufficient data to calculate CL/F.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"The Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing which resulted in insufficient data to calculate CL/F.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"The Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing which resulted in insufficient data to calculate CL/F.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"The Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing which resulted in insufficient data to calculate CL/F.","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"The Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing which resulted in insufficient data to calculate CL/F.","groupId":"OG004","spread":"NA","value":"NA"},{"comment":"The Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing which resulted in insufficient data to calculate CL/F.","groupId":"OG005","spread":"NA","value":"NA"},{"comment":"The Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing which resulted in insufficient data to calculate CL/F.","groupId":"OG006","spread":"NA","value":"NA"},{"comment":"The Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing which resulted in insufficient data to calculate CL/F.","groupId":"OG007","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"description":"Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1, and within 4 hours prior to dosing on Day 1 of Cycle 2.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG000","title":"Phase I (Tablet) Cobimetinib (0.6 mg/kg)"},{"description":"Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG001","title":"Phase I (Tablet) Cobimetinib (0.8 mg/kg)"},{"description":"Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG002","title":"Phase I (Tablet) Cobimetinib (1 mg/kg)"},{"description":"Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG003","title":"Phase I (Suspension) Cobimetinib (0.6 mg/kg)"},{"description":"Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG004","title":"Phase I (Suspension) Cobimetinib (0.8 mg/kg)"},{"description":"Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG005","title":"Phase I (Suspension) Cobimetinib (1 mg/kg)"},{"description":"Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG006","title":"Phase I (Suspension) Cobimetinib (1.33 mg/kg)"},{"description":"Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG007","title":"Phase II (Suspension) Cobimetinib (1 mg/kg)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Please note that for this Outcome Measure, the Apparent Clearance of Cobimetinib could not be calculated/estimated as PK samples were collected only up to 24hr post dosing.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21; pre-dose on Cycle 2 Day 1 (pre-dose=within 4 hours prior to dose; cycle length=28 days)","title":"Apparent Clearance (CL/F) of Cobimetinib","type":"SECONDARY","unitOfMeasure":"L/hr"}